In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
NEW YORK (Reuters Health) – The addition of bevacizumab (Avastin; Genentech/Roche) to the standard docetaxel and prednisone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) did not…
NEW YORK (Reuters Health) – The 2009 influenza A(H1N1) pandemic caused severe illness and mortality in cancer patients with solid tumors, investigators report in Cancer online February 22.…
NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%,…
NEW YORK (Reuters Health) – When patients with advanced gastric cancer have not benefitted from one or two chemotherapy regimens for metastatic disease, salvage chemotherapy improves their overall…
NEW YORK (Reuters Health) – Two independent studies have shown that reduced-activity variants of the cytochrome P450 2D6 (CYP2D6) enzyme are not associated with poorer disease control in…
NEW YORK (Reuters Health) – The success of radiofrequency ablation (RFA) for small renal tumors is strongly dependent on tumor size, according to a study in the April…
NEW YORK (Reuters Health) – The reduced risk of developing invasive breast cancer with adjuvant tamoxifen therapy after lumpectomy and radiation for ductal carcinoma in situ (DCIS) is…
NEW YORK (Reuters Health) – The selective inhibitor of Janus kinase (JAK) 1 and 2, ruxolitinib, significantly reduces spleen size and other debilitating symptoms in patients with myelofibrosis…
NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue…
NEW YORK (Reuters Health) – Men 60 years old and younger have excellent quality-of-life outcomes after proton therapy for prostate cancer, according to findings published in the January…
